Autopsy report · NCT01964378

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

“low accrual made the study no longer feasible/decision not related to safety and efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years before it stopped.
• 200 participants enrolled.
• Results were posted on the registry 4 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Tris Pharma, Inc.

Sponsor type

Industry

Conditions

Pain; Neoplasms; Chronic Pain

Interventions

Cebranopadol; Morphine Prolonged Release

Participants

200

Sites

42

Countries

Austria, Belgium, Bulgaria, Chile, Croatia, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia and more

Trials that died the same way

• Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
  “Study was closed to low accrual.” (75% match in meaning)
• Pre-operative Zoledronate in Triple Negative Breast Cancer
  “The study stopped prematurely due to the low accrual rate” (74% match in meaning)
• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
  “The study was terminated due to low accrual.” (74% match in meaning)
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
  “Study closed due to slow accrual and lack of efficacy.” (73% match in meaning)
• Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
  “the study had a low accrual rate” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.